SCHEMBL216170

SCHEMBL216170

COC(=O)c1cc2ccc(OC)cc2[nH]1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 6/20 0.67
PDGFRB P09619 4/20 0.67
PDGFRA P16234 3/20 0.67
NPC1 O15118 5/20 0.59
RAB9A P51151 5/20 0.59
HRH4 Q9H3N8 1/20 0.59
KMT2A Q03164 6/20 0.59
MEN1 O00255 3/20 0.59
KDM4E B2RXH2 1/20 0.57
ALDH1A1 P00352 1/20 0.57
LMNA P02545 1/20 0.57
HPGD P15428 1/20 0.57
HTT P42858 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.57
RXFP1 Q9HBX9 2/20 0.56
XDH P47989 2/20 0.56
HDAC1 Q13547 1/20 0.54
HDAC2 Q92769 1/20 0.54
MTNR1A P48039 1/20 0.53
MTNR1B P49286 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29368200 1.00 FLT3 (0.67) FLT3PDGFRBPDGFRANPC1RAB9A
SCHEMBL30071254 0.88 NPC1 (0.55) FLT3PDGFRBPDGFRANPC1RAB9A
SCHEMBL20495078 0.88 NPC1 (0.55) FLT3PDGFRBPDGFRANPC1RAB9A
SCHEMBL31361409 0.87 PDGFRB (0.77) FLT3PDGFRBPDGFRANPC1RAB9A
SCHEMBL1104006 0.87 PDGFRB (0.77) FLT3PDGFRBPDGFRANPC1RAB9A
SCHEMBL28581099 0.86 ULK1 (0.63) FLT3PDGFRBPDGFRANPC1RAB9A
SCHEMBL25721354 0.86 CA2 (0.57) FLT3PDGFRBPDGFRANPC1RAB9A
SCHEMBL24113306 0.85 FLT3 (0.68) FLT3PDGFRBPDGFRANPC1RAB9A
SCHEMBL335655 0.85 FLT3 (0.68) FLT3PDGFRBPDGFRANPC1RAB9A
SCHEMBL30189510 0.85 FLT3 (0.68) FLT3PDGFRBPDGFRANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 236 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007137168-A2 BRIDGED ARYL PIPERAZINES DERIVATIVES USEFUL FOR THE TREATMENT OF CNS, GI-URINARY AND REPRODUCTIVE DISORDERS JANSSEN PHARMACEUTICA N.V. (BE) 2007-11-29 WO claimed
CN-114729004-B Heterocyclic compounds 日商泛美克斯股份有限公司 2025-06-03 CN disclosed
CN-119838020-A Antibody drug conjugates comprising toxins having polar groups and uses thereof 尹图赛利有限公司 2025-04-18 CN disclosed
US-12202829-B2 Heterocyclic compound FIMECS, INC. (JP) 2025-01-21 US disclosed
CN-119325468-A Heterocyclic derivatives, compositions and uses thereof 北京丹擎医药科技有限公司 2025-01-17 CN disclosed
EP-4452328-A1 ANTIBODY DRUG CONJUGATES COMPRISING TOXINS WITH POLAR GROUPS AND USES THEREOF Intocell, Inc. (KR) 2024-10-30 EP disclosed
CN-118414170-A Antibody drug conjugates comprising toxins having polar groups and uses thereof 尹图赛利有限公司 2024-07-30 CN disclosed
WO-2023241322-A1 HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF DANATLAS PHARMACEUTICALS CO., LTD. (CN) 2023-12-21 WO disclosed
US-20230374017-A1 COMPOSITIONS AND METHODS FOR ACTIVATING PYRUVATE KINASE THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2023-11-23 US disclosed
US-20230242529-A1 HETEROCYCLIC COMPOUND FIMECS, INC. (JP) 2023-08-03 US disclosed
US-5686610-A Pyridyl piperazine compound PHARMACIA & UPJOHN COMPANY (US) 1997-11-11 US disclosed
US-5599930-A Substituted indoles as anti-AIDS pharmaceuticals THE UPJOHN COMPANY (US) 1997-02-04 US disclosed
EP-0594702-B1 SUBSTITUTED INDOLES AS ANTI-AIDS PHARMACEUTICALS UPJOHN CO (US) 1997-01-29 EP disclosed
US-5563142-A INHIBITORS OF VIRAL REVERSE TRANSCRIPTASE THE UPJOHN COMPANY (US) 1996-10-08 US disclosed
EP-0507861-B1 DIAROMATIC SUBSTITUTED ANTI-AIDS COMPOUNDS UPJOHN CO (US) 1996-09-11 EP disclosed
US-5489593-A Anti-aids piperazines THE UPJOHN COMPANY (US) 1996-02-06 US disclosed
EP-0594702-A1 SUBSTITUTED INDOLES AS ANTI-AIDS PHARMACEUTICALS. UPJOHN CO (US) 1994-05-04 EP disclosed
WO-1993001181-A1 SUBSTITUTED INDOLES AS ANTI-AIDS PHARMACEUTICALS THE UPJOHN COMPANY (US) 1993-01-21 WO disclosed
EP-0507861-A1 DIAROMATIC SUBSTITUTED ANTI-AIDS COMPOUNDS. UPJOHN CO (US) 1992-10-14 EP disclosed
WO-1991009849-A1 DIAROMATIC SUBSTITUTED ANTI-AIDS COMPOUNDS THE UPJOHN COMPANY (US) 1991-07-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242529-A1 HETEROCYCLIC COMPOUND XIAP, BIRC5, BIRC3 FLT3 4005/4885PDGFRB 4647/4885PDGFRA 4686/4885
US-12202829-B2 Heterocyclic compound XIAP, BIRC5, BIRC3 FLT3 4005/4885PDGFRB 4647/4885PDGFRA 4686/4885
US-20230374017-A1 COMPOSITIONS AND METHODS FOR ACTIVATING PYRUVATE KINASE PCK1, PDK2, PDK1 FLT3 734/4885PDGFRB 2464/4885PDGFRA 2626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.